Clinical Trials Logo

Filter by:
NCT ID: NCT05489263 Recruiting - Acute Kidney Injury Clinical Trials

A Predictive Score System for AKI Following Pediatric Cardiac Surgery

Start date: April 1, 2022
Phase:
Study type: Observational

Acute kidney injury (AKI) has been recognized as a typical post- operative complication among the children undergoing surgical repair of a congenital cardiac defect. It is associated with increased morbidity and mortality in the intensive care unit and a higher utilization of hospital resources. However, how to precisely identify those who have greater hazard to encounter postoperative AKI seems ambiguous.

NCT ID: NCT05489211 Recruiting - Colorectal Cancer Clinical Trials

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Start date: September 6, 2022
Phase: Phase 2
Study type: Interventional

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

NCT ID: NCT05489055 Recruiting - Clinical trials for Contrast Media Adverse Reaction

Effects of Contrast Media Temperature on Image Quality and Clinical Adverse Events in Coronary CTA

Start date: February 1, 2022
Phase: N/A
Study type: Interventional

Extrinsic prewarming of iodinated CT contrast media (CM) to body temperature reduces viscosity and injection pressures. However, guideline recommendations on the necessity to prewarm iodinated CM are conflicting. And studies examining the effect of extrinsic warming CM for coronary CTA(CCTA) on clinical adverse events and image quality are lack. Enrolled patients of chest pain or coronary artery disease screening were eligible for this a double-blinded, randomized noninferiority trial, and equally allocated into two group randomly: BBT-CM (basic body temperature) group received 37°C CM; RT-CM (room temperature) group received ~23°C CM. A state-of-the-art individualized CM (iopamidol at 370 mg I/mL) injection protocol was used, based on body weight.

NCT ID: NCT05489016 Recruiting - Clinical trials for Coronary Heart Disease

HuoXin Pills Intervention on Patients With Coronary Heart Disease After Drug-Coated Balloon Implantation

HAPPY-DCB
Start date: August 5, 2022
Phase: Phase 4
Study type: Interventional

This trial is a multi-center, randomized, double-blind, placebo, parallel controlled study. Objectively evaluates the curative effect of Huoxin Pills (concentrated pills) intervention on improving the prognosis of patients with coronary heart disease after drug-coated balloon implantation from a functional point of view. Huoxin Pill(concentrated pills), a traditional Chinese medicine, has been prescribed widely in the treatment of coronary heart disease, angina pectoris, and other diseases.440 patients were selected and followed up for one year. The quantitative blood flow score of the target vessel, late lumen loss, MACE incidence, and safety index were observed at 12 months.

NCT ID: NCT05489003 Recruiting - Clinical trials for Chronic Pancreatitis

Fatigue, Psychological Comorbidity and Quality of Life Among Patients With Chronic Pancreatitis in China.

Start date: August 1, 2022
Phase:
Study type: Observational

This study will investigate the status of fatigue, psychological comorbidity and quality of life among patients with chronic pancreatitis in China and analyze their influencing factors.

NCT ID: NCT05488860 Recruiting - Skin Diseases Clinical Trials

Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases

Start date: July 30, 2022
Phase: N/A
Study type: Interventional

Piezoelectric drived microneedling treats refractory skin disorders using hollow microneedles assisted by ultrasound. Mechanically, the injection of medicine by hollow microneedling could makes the distribution of medicine more evenly. And the addition of ultrasound technique improves the effectiveness of microneedling. Investigators plan to conduct a pilot study to investigate the efficacy of using piezoelectric drived microneedles in treating refractory skin diseases.

NCT ID: NCT05488821 Recruiting - Clinical trials for Advanced Solid Tumors Harboring MAPK Pathway Alterations

Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.

Start date: June 14, 2022
Phase: Phase 1
Study type: Interventional

This is an open label, phase 1 clinical study to evaluate the safety and tolerability of different doses of QLH11906 monotherapy in patients with relapsed/refractory, unresectable locally advanced or metastatic advanced solid tumors with abnormal MAPK pathway, and determine the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD, if MTD cannot be determined) and Recommended Dose in Phase II Clinical Studies (Recommended Phase II Dose, RP2D).

NCT ID: NCT05488314 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

METalmark
Start date: December 13, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to identify the recommended Phase 2 combination dose (RP2CD[s]) of the amivantamab and capmatinib combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection), and to evaluate the antitumor effect of the amivantamab and capmatinib combination therapy in mesenchymal-epithelial transition (MET) exon 14 skipping mutation and MET amplified NSCLC, when administered at the selected RP2CD(s) in Phase 2 (expansion).

NCT ID: NCT05488132 Recruiting - Clinical trials for Acute Myeloid Leukemia, in Relapse

Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Start date: April 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety and efficacy of anti-Siglec-6 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.

NCT ID: NCT05488067 Recruiting - Alagille Syndrome Clinical Trials

Atorvastatin Therapy on Xanthoma in Alagille Syndrome

Start date: March 22, 2022
Phase: Phase 4
Study type: Interventional

To observe the efficacy and safety of atorvastatin on xanthoma in Alagille syndrome through a prospective study.